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Autoimmune disorders (AID) have been increasingly observed in association with primary
immunodeficiencies (PIDs). Here, we discuss the interface between PID and AID, focusing
on autoimmune manifestations early in life, which can be diagnostic clues for underlying
PIDs. Inflammatory bowel disease in infants and children has been associated with
IL-10 and IL-10R deficiencies, chronic granulomatous disease, immunedysregulation-
polyendocrinopathy-enteropathy-X-linked syndrome (IPEX), autoinflammatory disorders,
and others. Some PIDs have been identified as underlying defects in juvenile systemic
lupus erythematosus: C1q-, IgA-, IgM deficiencies, alterations of the IFN-α pathway
(in Aicardi–Goutières syndrome due to TREX1 mutation). IPEX (due to FOXP3 mutation
leading to Treg cell deficiency), usually appearing in the first months of life, was recently
observed in miscarried fetuses with hydrops who presented with CD3+ infiltrating lym-
phocytes in the pancreas. Hemophagocytic lymphohistiocytosis due to perforin deficiency
was also identified as a cause of fetal hydrops. In conclusion, PID should be suspected
in any infant with signs of autoimmunity after excluding transferred maternal effects, or in
children with multiple and/or severe AID.
Keywords: primary immunodeficiency, fetal autoimmunity, IPEX, juvenile systemic lupus erythematosus, inflam-
matory bowel disease
Introduction
An increasing number of reports have shown that a substantial proportion of patients with primary
immunodeficiencies (PID) develop autoimmune disorders (AID), in addition to increased suscep-
tibility to infections (1, 2). These findings are paradoxical if natural tolerance is thought to result
from negative selection, but they are compatible with the notion that physiological autoimmunity
is necessary for self-tolerance. In this case, immunodeficiency is the cause of autoimmunity; in fact,
they are the two sides of the same coin. Monogenic PIDs may provide unique opportunities to
uncover the genetic bases and mechanisms of complex AID, the study of which has already helped
to unravel the pathways that drive autoimmunity. For example, studies of immunedysregulation-
polyendocrinopathy-enteropathy-X-linked syndrome (IPEX), which is caused by FOXP3 gene
mutations, have critically established the fundamental role of regulatory T cells (Tregs) in natural
tolerance, and PID-AID associations have consolidated the notion of dominant tolerance. Thus,
contrary to classical notions of “recessive” tolerance (lymphocyte deletion or anergy) that interpret
autoimmunity as resulting fromexcess (auto) reactivity, the PID-AID associationswould rather indi-
cate deficiency in mechanisms that physiologically regulate autoreactivities that are always present.
Autoimmune phenomena, however, have also been observed in other types of PIDs, notably in
innate immunity defects (1, 2). Although the association between complement deficiencies and
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systemic lupus erythematosus (SLE) has long been known, it
is now recognized that defects in phagocytes and other innate
immunity mechanisms also present autoimmunity. In our view,
the concept of AID should actually be expanded to include innate
disorders that are classified as “autoinflammatory diseases” (3);
thus, there is no a priori reason, evolutionary or otherwise, to
restrict AID to adaptive immunity. On the contrary, all “ridding”
functions are potentially aggressive if they escape regulation, par-
ticularly in the innate system. This view predicts that AID should
eventually be found in invertebrates.
Here, we discuss the interface between primary immunodefi-
ciency and AID, focusing on early-onset (including intrauterine)
manifestations. Our aim is to draw attention to AID in early life
as being clinical manifestations of underlying PIDs.
Heterogeneity of PID-AID Associations
As previously noted (1), a handful of PIDs are systematically
associated with AID, such that we consider them to bemonogenic
autoimmune diseases. However, these PIDs are heterogeneous in
terms of the age of onset and clinical manifestations (Table 1).
IPEX is a life-threatening condition, with some patients devel-
oping AID already in fetal life and rarely surviving infancy in
the absence of hematopoietic stem cell transplantation (HSCT);
type I diabetes, autoimmune enteropathy leading to chronic diar-
rhea, inflammatory bowel disease (IBD), and cytopenias are the
most common autoimmune manifestations; affected infants also
present severe allergy and high IgE levels (4, 5). Omenn syndrome
(OS), which is also a life-threatening condition, usually appears
in the first months after birth through a combination of severe
immunodeficiency with allergic hyperinflammation and autoim-
munity, with predominant skin involvement and high levels of
IgE. OS is also a consequence of loss of regulation because of the
highly restricted, oligoclonal CD4 TCR (T-cell receptor) reper-
toire, resulting from hypomorphic (severe but not null) muta-
tions in critical genes for V-region rearrangement or lympho-
cyte development (RAG1, RAG2, and other SCID-related genes,
including IL7RA, IL2RG, ADA,DCLRE1C, Ligase IV gene,CHD7,
RMRP, AK2) (6). Autoimmune polyendocrinopathy candidiasis
ectodermal dystrophy (APECED), which is caused by AIRE gene
defects, is the prototypic disorder of central (thymic) tolerance
and is much less severe, with mucocutaneous candidiasis and
autoimmune endocrinopathies usually appearing in childhood
(7). Mucocutaneous candidiasis is likely of autoimmune origin,
caused by auto-antibodies to cytokines involved in anti-fungal
immunity (anti-IL-17) (8). Autoimmune lymphoproliferative syn-
drome (ALPS) represents a group of lymphocyte apoptosis dis-
orders (due to Fas mutations in most cases) with AID targets
predominantly in blood cells (2). ALPS usually appears in child-
hood and may improve with age. Complete C1q deficiency is
intimately associatedwith juvenile SLE development (9). Note that
different autoimmune phenotypes are associated with different
genetic defects (1), and a major question concerning the mech-
anisms of disease continues to be the restricted tissue “targeting”
of these conditions.
There is another group of PIDs that are strongly associated
with AID (more than 20% of affected patients demonstrate
autoimmune manifestations), in which two of the most frequent
PIDs are included: IgA deficiency and common variable immun-
odeficiency (CVID) (Table 2) (1, 2); the mechanisms underlying
pathogenic autoreactivity are not entirely clear yet.
There are a few PIDs in which AID is rarely or never observed,
even in patients with chronic or recurrent infections (1). Exam-
ples of such PIDs include IL-12/IL-23 – IFN-γ axis deficiencies,
IRAK-4 deficiency, autosomal dominant Hyper-IgE syndrome
(due to STAT3mutations leading to deficiency of Th17 cells), and
congenital asplenia.
Fetal Autoimmune Diseases Associated
with PIDs
IPEX typically manifests early in life: 45% of patients in the liter-
ature presented symptoms in the neonatal period, and there were
11 cases at birth (4). These observations clearly suggest fetal onset
of AID, which we have recently demonstrated in two unrelated
families (5). In one family, a newborn with intrauterine growth
restriction presented at birth with type-1 diabetes, diarrhea,
thrombocytopenia, eczematous dermatitis, eosinophilia, high IgE
levels, and autoantibodies to pancreatic islet antigens at 4 days
of age, with negative maternal serology. In a second family,
a different FOXP3 mutation was identified in two miscarried
monochorionic twin male fetuses, who died at 21weeks of gesta-
tion due to hydrops; the fetuses demonstrated CD3+ infiltrating
lymphocytes in their pancreases. Both families had a history of
repeated miscarriages of males in consecutive generations, as
well as premature babies who developed severe fatal diarrhea
immediately after birth. Additionally, at the Children’s Hospi-
tal of Philadelphia, in the same family, two miscarried fetuses
who died due to hydrops were identified as carrying another
FOXP3 mutation (Sara L. Reichert, personal communication,
2014).
We are aware of only limited additional observations of fetal
AID: a case of OS at birth due to an IL7Rα deficiency (10) and
a few reports on fetal hydrops associated with HLH (hemophago-
cytic lymphohistiocytosis), including two perforin-deficient twins
(11); these cases were described as non-immune hydrops but,
as discussed above, we would classify them as AID due to
innate immunity mechanisms. Otherwise, in IPEX, autoimmune
hemolytic anemia may be the cause of fetal hydrops (5).
In terms of classical views of tolerance, it is surprising that
“break of tolerance” can occur when immune system is still
immature. Rather than being “broken”, however, we suggest
that establishment of tolerance itself was severely compromised
in these cases. Thus, given the current knowledge of the age-
dependent development of the various lymphocyte classes and
effector functions, as well as on the ability of fetuses to produce
immune responses (12), it is not surprising that pathological
fetal autoimmunity exists and that there is enough time before
birth to produce autoantibodies and to develop autoreactive T
lymphocytes, which cause destruction of pancreatic beta-cells or
other lesions.
Autoimmune diseases in fetal life are, indeed, extremely rare
and have always been associated with severe PIDs; hence, all
newborns with suspected AID should be investigated for PID.
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TABLE 1 |Main characteristics of some monogenic PIDs systematically associated to autoimmune manifestations.
PID Inheritance Mutated gene Main defect Age of onset Susceptibility to infection Main autoimmune manifestations Other features
IPEX X-linked FOXP3 Deficiency of regulatory
T cells
Neonatal period or
first months of life
Staphylococcus aureus (sepsis) Type-1 diabetes mellitus, enteropathy
(leading to chronic diarrhea), IBD,
hypothyroidism, cytopenias
Failure to thrive, atopic-like
eczema, food allergy, high IgE
levels, eosinophilia
APECED AR AIRE Impaired negative
thymic selection of
T cells
Childhood Only chronic mucocutaneous
candidiasis
Hypoparathyroidism, hypoadrenalism,
hypogonadism, type-1 diabetes
mellitus, hepatitis, alopecia, vitiligo
Enamel dysplasia
ALPS AR, AD FAS, FASL,
CASP10, CASP8,
PRKCD, NRAS
Defects of lymphocyte
apoptosis
Childhood Normal resistance to infection Hemolytic anemia, thrombocytopenia,
Evans’ syndrome, neutropenia
Lymphadenopathy,
splenomegaly, high numbers of
TCR αβ double negative T cells
in peripheral blood
Omenn
syndrome
AR in most
cases
Hypomorphic
mutations of RAG1,
RAG2, IL7RA, ADA,
IL2RG, others
Severe combined T
and B deficiency
Neonatal period or
first months of life
A wide variety of infectious
agents: fungi, viruses, extra
and intracellular bacteria,
including mycobacteria
Generalized exfoliative erythroderma
(the “red baby”), enteropathy, alopecia
Hepatosplenomegaly,
eosinophilia, high IgE levels,
oligoclonal T cell repertoire
C1q
deficiency
AR C1QA, C1QB,
C1QC
Complement
deficiency
Childhood Encapsulated bacteria
(Streptococcus pneumoniae,
Haemophilus influenzae)
SLE with severe skin involvement,
kidney and CNS also affected in most
cases
–
HLH AR PERF1, STX11,
STXB2, UNC13D,
or UNC18B
Defects of cytotoxic
granules of natural killer
cells and cytotoxic
T lymphocytes
Infancy, childhood,
rarely later onset
Viral infections may be
triggering factors; wide variety
of infectious agents observed in
neutropenic patients
Systemic hyperinflammation with high
proinflammatory cytokine response, no
classical autoimmune diseases
Fever, hepasplenomegaly,
cytopenias, erythrophagocytosis,
hypertriglyceridemia,
hyperferritinemia
NOMID/
CINCAa
AD NLRP3/CIAS1 Autoinflammatory
disease
(cryopyrinopathy)
Neonatal period or
first weeks of life
Normal resistance to infections Exacerbated inflammation, continuous
fever, no classical autoimmune diseases
Urticarial cutaneous rash,
chronic aseptic neutrophilic
meningitis, arthropathy
DIRAa AR IL1RN Autoinflammatory
disease (lack of IL-1
receptor antagonist)
Infancy, early
childhood
Normal resistance to infections Exacerbated inflammation, no classical
autoimmune diseases
Pustular dermatitis and multifocal
aseptic osteomyelitis
AD, autosomal dominant; AR, autosomal recessive; ALPS, autoimmune lymphoproliferative syndrome; APECED, autoimmune polyendocrinopathy candidiasis ectodermal dystrophy; CINCA, chronic infantile, neurological, cutaneous and
articular syndrome; CNS, central nervous system; DIRA, deficiency of IL-1 receptor antagonist; IBD, inflammatory bowel disease; HLH, hemophagocytic lymphohistiocytosis; IPEX, immunedysregulation-polyendocrinopathy-enteropathy
X-linked syndrome; NOMID, neonatal-onset multisystem inflammatory disease; SLE, systemic lupus erythematosus; TCR, T-cell receptor.
aAutoinflammatory diseases.
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TABLE 2 |Main characteristics of some PIDs strongly associated to autoimmune manifestations (present in more than 20% of the PID cases).
PID Inheritance Mutated gene Main defect Age of onset Susceptibility to infections Autoimmune manifestations Other features
Wiskott–Aldrich
syndrome (WAS)
X-linked WAS Combined T and B
deficiency
Infancy Encapsulated bacteria
(Streptococcus pneumoniae),
some fungi (Pneumocystis
jiroveci)
Hemolytic anemia,
neutropenia, IgA
nephropathy, arthritis, IBD
Bleeding diathesis,
thrombocytopenia with
small platelets, eczema,
high IgE levels
IgA Deficiency Unknown Unknown Antibody deficiency Childhood,
adolescence,
adulthood
Recurrent respiratory infections,
giardiasis
Hypothyroidism, cytopenias,
SLE
Respiratory allergic
symptoms
Common variable
immunodeficiency
(CVID)
Unknown in
most cases,
AR
Unknown in most
cases, ICOS, CD19,
TNFRSF13B (TACI),
TNFRSF13C (BAFF-R),
others
Antibody deficiency
(low IgG, IgA and/or
IgM)
Adolescence,
adulthood
Recurrent respiratory infections
(often pneumonias due to
encapsulated bacteria)
Thrombocytopenia, hemolytic
anemia, neutropenia, sicca
syndrome, rheumatoid
arthritis, IBD, SLE, others
Granulomatous disease
and splenomegaly in
some cases
Chronic
granulomatous
disease (CGD)
X-linked, AR CYBB (gp91phox),
CYBA (p22phox),
NCF1 (p47phox),
NCF4 (p40phox)
Deficiency of
microbicidal activity of
phagocytes
Infancy or childhood in
X-linked cases,
childhood in AR
patients
Catalase-positive bacteria
(Staphylococcus aureus,
Burkholderia cepacia, Serratia,
others) and fungi (mainly
Aspergillus), mycobacteria
species, including BCGitis
IBD Formation of granulomas
in gastrointestinal,
respiratory, and urinary
tracts, abscesses in liver,
lungs, and even in spleen
C4 deficiency AR C4A, C4B Complement
deficiency
Childhood Encapsulated bacteria SLE –
C2 deficiency AR C2 Complement
deficiency
Childhood Encapsulated bacteria SLE, vasculitis –
AR, autosomal recessive; AD, autosomal dominant; IBD, inflammatory bowel disease; SLE, systemic lupus erythematosus.
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PIDs Associated with Juvenile Systemic
Lupus Erythematosus
Deficiencies of the early components of the classical complement
pathway have long been recognized as strong risk factors for SLE
development (13). Complete C1q deficiency may be considered
to be a monogenic SLE form, because more than 90% of affected
patients develop severe disease, usually beginning early in life.
IgA deficiency was identified in 1–6% of SLE patients and is
10–50 times more frequent in SLE than in the general population.
We have recently investigated complement and immunoglobulin
deficiencies in patients with both juvenile- and adult-onset SLE
(9, 14). Among 72 children and adolescents, 16 (22%) were iden-
tified with complement [C1q (n= 2), C2 (n= 2), C4 (n= 2)] or
immunoglobulin [IgA (n= 3), IgM (n= 3), IgG2 (n= 4)] defi-
ciencies. The only two cases identified before 2 years of age were
associated to PIDs: one C1q deficiency of fatal course and a
persistent IgM deficiency. In 5 of the 6 cases with complement
deficiencies, SLE manifestations began before 10 years of age. In
contrast, no complement deficiency was identified among 300
adult-onset SLE, whereas 3 patients had selective IgA deficiency,
and 24 showed isolated IgM deficiency (<30mg/dL), which was
repeatedly observed in the follow-up of 5 patients. Although IgM
deficiency has not been consistently reported as being a risk factor
for SLE development, note the following three details: (a) observa-
tions in murine models indicate that IgM autoantibodies may be
protective as neutralizers of IgG autoantibodies; (b) deficiencies
in serum and/or secretory IgM resulted in elevated levels of lupus-
type IgG antibodies; and (c) these clinical cases all support the idea
that a lack of IgM production may be relevant to SLE pathophysi-
ology [reviewed in Ref. (9)]. Severe hypogammaglobulinemia was
not observed in either juvenile or adult patients in our cohort, but
it has been reported that SLE complicates the clinical course of
CVID (13). Analyzing gene copy numbers for C4A and C4B in
the same groups, juvenile SLE patients presented lower values than
healthy controls and adult-onset SLE patients (Kaline Pereira and
Luis Andrade, personal communication).
Aicardi–Goutières syndrome (AGS), another form of early-
onset SLE, is seen to be a monogenic form of lupus that brought
light to the role of type I interferons and TREX1 gene mutations
in SLE pathophysiology (15). AGS is a genetically determined
encephalopathy that phenotypically overlaps with SLE (erythe-
matous skin lesions, oral ulcers, arthritis, thrombocytopenia,
leukopenia, positive antinuclear antibodies), and its autosomal-
recessive (AR) form is associated with high IFN-α production.
Similar to AGS, SLE is associated with alterations in type I inter-
feronmetabolism,with upregulation of type I IFN-inducible genes
in peripheral blood cells. TREX1, which encodes an exonucle-
ase (a DNAse type III), is the most frequently mutated gene in
AGS (15), resulting in intracellular accumulation of abnormal
single-stranded DNA, which may explain the high levels of IFN-
α observed. TREX1 mutations were observed more frequently
(0.5–3%) in a large cohort of SLE patients than in healthy con-
trols, thus supporting the hypothesis of TREX1 involvement in
lupus pathogenesis.
Systemic lupus erythematosus has also been described in
some patients with AR Hyper-IgE syndrome caused by DOCK8
mutations, as well as in some patients with prolidase deficiency,
a rare metabolic disease (15). In both monogenic diseases, the
patients also presented with atopic-like skin manifestations and
high serum IgE levels.
A homozygous missence mutation in the PRKCD gene (encod-
ing protein-kinase delta) was recently identified in three SLE
children from a consanguineous family (16). It has been observed
that Prkcd participates in the deletion of autoreactive B cells, and
deficient mice have demonstrated systemic autoimmunity and B
cell proliferation.
Interestingly, other PIDs are systematically associated with
autoimmune diseases but not with SLE (Table 1). APECED (due
to AIRE mutations) is of particular interest because hundreds
of patients reportedly reached adulthood with several organ-
specific AID, but did not develop SLE, suggesting that defective
thymic selection of lymphocytes should not represent a rele-
vant pathogenic mechanism (7, 13). Reinforcing this idea, SLE
has rarely been described among Down syndrome patients, who
demonstrate lower thymic expression of AIRE and are at high
risk of developing organ-specific autoimmune diseases, but not
lupus (17).
The evidence above that an underlying defect is more common
in pediatric SLE than in adult forms suggests that SLE appearance
in the first years of life should lead to the suspicion of a PID.
PIDs in Early-Onset Inflammatory Bowel
Disease
Inflammatory bowel disease in infants and young children has
been increasingly recognized as being associated with monogenic
defects, particularly PIDs such as IL-10 and IL-10R deficien-
cies, chronic granulomatous disease, Wiskott-Aldrich syndrome,
IPEX, IPEX-like syndromes (CD25 deficiency and gain of func-
tion in STAT1 signaling), atypical SCID (severe combined
immunodeficiency),OS,NEMO(nuclear factor kB essentialmod-
ulator) deficiency, XIAP (X-linked inhibitor of apoptosis) defi-
ciency, and autoinflammatory disorders (Tables 1 and 2) (4,
18, 19). PIDs associated with “early“ or “very early-onset” IBD
(identified before 10 or 6 years of age, respectively) thus repre-
sent various defects of adaptive immunity (including regulatory
T cells and anti-inflammatory cytokines), innate immunity, as
well as neutrophil dysfunctions, but not complement deficien-
cies (19).
In a multicentric study with 66 IBD patients younger than
5 years of age and different ethnic origins, 16 (24%) cases demon-
strated IL-10 or IL-10R deficiencies (18), with precocious symp-
toms in the first months of life (infantile IBD forms), and peri-
anal disease in most cases. Although age of onset, location, and
other characteristics of the intestinal disease, togetherwith clinical
and laboratorial features, may indicate an underlying deficiency,
phenotypes usually overlap, and genetic testing should be per-
formed not only to identify monogenic defects but also to select
appropriate treatment (18, 19). In some entities, including IL-
10 signaling defects, HSCT represents a promising therapeutic
option and sometimes the only option to ensure patient survival.
As a general rule, abnormal susceptibility to infections and the
presence of other autoimmune and/or inflammatory phenomena
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suggest an underlying PID in infants and young children with an
IBD picture.
Most Autoinflammatory Diseases Manifest
Early in Life
Monogenic autoinflammatory diseases (MAID) are classified as
PIDs (2) and comprise a growing number of recently identi-
fied defects, most of which manifest in childhood, and some
of which typically manifest in infancy (3, 20). The study of
MAID patients has unraveled key regulatory and effector innate
immunity pathways and demonstrated that uncontrolled pro-
inflammatory cytokine and chemokine responses can be life
threatening and cause significant organ damage as do classical
AIDmediated by autoantibodies and autoreactive T lymphocytes.
Familial Mediterranean fever (FMF) and tumor necrosis factor)
ReceptorAssociated Periodic Syndrome (TRAPS) have been iden-
tified as the two most frequent entities in various population
groups, including a Brazilian one, FMF presenting significant
prevalence in eastern Mediterranean populations (3).
Monogenic autoinflammatory diseases characteristically
present with non-infectious fever (continuous in some diseases
or periodic in others) and systemic and/or disease-specific
organ inflammation. The skin, bones, joints, eyes, and central
nervous system are the most common affected sites in MAIDs
(3). Extensive skin lesions in infants should be a warning
sign for MAIDs: generalized urticarial, pustular, erythematon-
odular or purpuric rash have been described in different
diseases. Abdominal pain is also a frequent feature in FMF and
TRAPS.
Some MAIDs begin in the first months of life (Table 1).
Neonatal-onset multisystem inflammatory disease (NOMID),
also called chronic infantile, neurological, cutaneous and artic-
ular (CINCA) syndrome, is the most severe form of cryopyrin
(a component of il-1β activating complex) associated periodic
syndromes (CAPS). CAPS are caused by autosomal dominant
gain-of-functionmutation in theNLRP3/CIAS1 gene, and approx-
imately 40% of patients with clinical NOMID/CINCA are neg-
ative for germ line mutation by Sanger sequencing. This defect
can be diagnosed clinically and it is characterized by continu-
ous low-grade fever, urticarial cutaneous rash, chronic aseptic
neutrophilic meningitis, and arthropathy, starting in the first
weeks of life (3). If untreated, patients develop permanent organ
damage as a consequence of persistent inflammation in the
affected organs. IL-1 blocking agents currently represent the most
effective treatment for NOMID/CINCA and the other cryopy-
rinopathies.
Another early-onset MAID is the deficiency of interleukin 1
receptor antagonist (DIRA) (Table 1). Affected patients present
with pustular (sparse, in crops or generalized) dermatitis, and
multifocal aseptic osteomyelitis, and periostitis; highly elevated
levels of acute phase reactants are also observed (3, 21). Fever is
often low grade or even absent in DIRA. A recombinant IL-1R
antagonist (anakinra) has been successfully used in DIRA patients
with rapid resolution of symptoms and normalization of acute
phase reactant levels.
Thus, MAID should be suspected in patients with manifesta-
tions of excessive inflammatory responses in infancy and child-
hood.
Autoimmune Diseases as Warning Signs
for PIDs in Infants and Children
After excluding transferred maternal effects, any AID in infants
should raise a PID suspicion. Persistent neonatal diabetes mel-
litus, autoimmune hypothyroidism, and autoimmune cytopenias
(primarily thrombocytopenia and hemolytic anemia) may be
precocious features of IPEX. Autoimmune cytopenias may also
complicate the course of DiGeorge syndrome, combined immun-
odeficiencies due to RAG1 gene mutations, and even SCID in
babies (10, 22, 23). Regarding AID in young children, an underly-
ing PID (or other monogenic disorder) should be investigated in
patients withmultiple and/or severe AID, primarily if recurrent or
serious infections are also present. In addition to fever of unknown
origin (episodic or continuous), extensive skin lesions of various
types, as well as persistent inflammation in the joints, bones, eyes,
and central nervous system should represent warning signs for
MAIDs in early life.
PIDs should also be considered as the underlying defect in cases
of fetal hydrops and recurrent miscarriages of unknown cause
(5, 11).
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